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During six months, we obtained Enterobacteriaceae isolates from patients with Gram-26 
negative bacteremia at a 1250-bed teaching hospital in St. Louis, Missouri, and compared 27 
carbapenem susceptibility with the presence of blaKPC, a transferable carbapenemase 28 
gene. Three (1.2%) out of 243 isolates were blaKPC-positive. Ertapenem non-29 




The serine carbapenemase KPC (Klebsiella pneumoniae carbapenemase) has emerged as 33 
a beta-lactamase capable of inactivating carbapenem antibiotics. First identified in 34 
Klebsiella pneumoniae (21), KPC since has been detected in other Enterobacteriaceae 35 
(7). The gene encoding KPC, blaKPC, is plasmid-transmissible among 36 
Enterobacteriaceae, which has implications for infection control (20, 3). The presence of 37 
blaKPC may not always result in carbapenem resistance in vitro (19), thereby impeding 38 
detection during routine work-up. KPC-producing bacteria have primarily been reported 39 
from the New York City area, however, blaKPC is present among Enterobacteriaceae 40 
isolates as far west as Arkansas (7). The aim of this study was to systematically screen 41 
Enterobacteriaceae bacteremia isolates for reduced susceptibility to carbapenems and to 42 
correlate results with the presence of blaKPC. 43 
Microbiological and molecular analyses were performed on bacterial isolates 44 
from inpatients with Enterobacteriaceae bacteremia at Barnes-Jewish Hospital (BJH) in 45 
St. Louis, Missouri. We included patients with bacteremia occurring between August 1, 46 
2006 and January 31, 2007. Isolates were tested for susceptibility to the three carbapenem 47 
antibiotics (ertapenem, imipenem, and meropenem) and non-carbapenem antibiotics, 48 
using the disk diffusion method (6) (Sensi-disc™ antibiotic disks; Becton, Dickinson and 49 
Co., Sparks, MD).  50 
Total DNA was extracted using the QIAamp DNA mini kit (QIAGEN, Valencia, 51 
CA). A real-time PCR assay of all available isolates (n=243) was developed for initial 52 
screening for the presence of blaKPC using primers and cycle parameters as described 53 
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previously (17). All isolates that were positive for the blaKPC gene by real-time PCR were 54 
confirmed with a conventional PCR assay as described previously (5). The three positive 55 
isolates were further characterized by DNA sequencing of the blaKPC PCR product using 56 
primers (F-5’-ATGTCACTGTATCGCCGTC-3’; R-5’-57 
CTCAGTGCTCTACAGAAAACC-3’) and thermocycling parameters described by Yigit 58 
et al. (21), with a BigDye® Terminator Cycle Sequencing Kit v3.1 (Applied Biosystems 59 
Inc., Foster City, CA) in a MJ Research PTC-200 DNA Engine thermal cycler (Bio-Rad 60 
Laboratories, Waltham, MA). Sequencing reactions were purified by ethanol 61 
precipitation, separated and analyzed using an ABI PRISM® 3100 Genetic Analyzer 62 
(ABI, Foster City, CA) following the manufacturers protocols. Forward and reverse 63 
strands of two independent PCR products from each isolate were sequenced. Sequences 64 
were aligned and compared to published sequences for the blaKPC-2 gene using Vector 65 
NTI v10.3.0 software (Invitrogen, Carlsbad, CA) and found to be identical to the blaKPC-2 66 
published sequence.  67 
Patient data on demographics, comorbidities, treatment, and in-hospital mortality 68 
were abstracted from medical records. The Washington University Human Research 69 
Protection Office approved this study. 70 
During the study period, 247 Enterobacteriaceae isolates were recovered from 71 
blood cultures at BJH. Four isolates were unavailable for testing, leaving 243 72 
Enterobacteriaceae isolates from 223 patients. Ninety isolates were (37.0%) Escherichia 73 
coli, 79 (32.5%) Klebsiella pneumoniae, 25 (10.3%) Enterobacter spp., 13 (5.3%) 74 
Proteus mirabilis, 11 (4.5%) Klebsiella oxytoca, 7 (2.9%) Citrobacter spp., 6 (2.5%) 75 
Serratia marcescens, and 12 others (4.9%). Seven (2.9%) isolates had reduced 76 
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susceptibility to ≥1 carbapenem (Table 1). Two isolates were resistant to all carbapenems 77 
tested; both were blaKPC-positive. Three isolates were only non-susceptible to ertapenem; 78 
none of these were blaKPC-positive.  79 
Three (1.2%) isolates carried the blaKPC gene. These isolates infected three 80 
patients (Table 2) and included one K. pneumoniae, one E. cloacae, and one P. mirabilis. 81 
In vitro ertapenem non-susceptibility detected blaKPC with high sensitivity [100% (3/3)] 82 
and high specificity [98.3% (236/240)], similar to imipenem [100% (3/3) and 100% 83 
(240/240), respectively] and meropenem [66.6% (2/3) and 99.6% (239/240)] (Table 1). 84 
The positive predictive value (PPV) of ertapenem non-susceptibility for detecting blaKPC 85 
was 43% (3/7) versus 100% (3/3) for imipenem, and 66.6% (2/3) for meropenem. The 86 
PPV of ertapenem as sole carbapenem showing resistance was 0% (0/3); the PPV of 87 
resistance to all three carbapenems for detecting blaKPC was 100% (2/2). One (33%) of 88 
the patients infected with a blaKPC(+) isolate and 41(18.6%) infected with a blaKPC(-) 89 
isolate died. 90 
KPC-positive bacteria were present in 1.3% (3/223) of bacteremia episodes in our 91 
study, which is relatively low. However, plasmid transfer and subsequent dissemination 92 
can occur (21, 3). In a study by Landman et al., susceptibility of K. pneumoniae isolates 93 
to carbapenems decreased from 97% to 76% within 5 years, probably due to blaKPC (11). 94 
In a U.S.-wide surveillance study, the prevalence of blaKPC among various 95 
Enterobacteriaceae was 0.5% (7), whereas a study of Brooklyn hospitals reported 38% 96 
prevalence in K. pneumoniae (11). Our data confirm that blaKPC is not restricted to the 97 
northeastern U.S. and warrant surveillance of carbapenem susceptibilities among 98 
Enterobacteriaceae. 99 
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Ertapenem has been proposed as the carbapenem that most accurately detects the 100 
presence of blaKPC by disk diffusion (12, 4). This may be because diameter cutoffs for 101 
inhibition zones were set more stringently for ertapenem than other carbapenems (6). 102 
Ertapenem was the most frequently non-susceptible carbapenem in our study; however, 103 
the positive predictive value of ertapenem non-susceptibility for identifying blaKPC was 104 
low (43%). This is possibly due to carbapenem resistance mediated by mechanisms other 105 
than blaKPC (15). Other studies (19, 16) have found that carbapenem susceptibility testing 106 
by the disk diffusion method is unreliable at predicting the presence of blaKPC. Possible 107 
explanations for undetected blaKPC-carriage are an unexpressed blaKPC gene, the inoculum 108 
effect (4), and misinterpretation of the resistance pattern to signify an ESBL-producer 109 
(16). A minimal inhibitory concentration (MIC) that is in the upper range of susceptibility 110 
may be the only indication of blaKPC. Lowering the imipenem MIC breakpoints (13) or 111 
PCR-based screening (9, 2) might increase the chance of detecting resistance.  112 
A limitation of our study is that we did not assess isolates for additional beta-113 
lactamases other than blaKPC, which is a constellation increasingly encountered (14, 12). 114 
We also had a relatively small sample size, a single-center design, and restricted analysis 115 
to bacteremia isolates. We did not test Gram-negative bacteria outside the 116 
Enterobacteriaceae family for blaKPC (18). In conclusion, our study is among the first 117 
prospective investigations into the endemic epidemiology of blaKPC-positive bacteria, 118 
demonstrating that blaKPC is currently present at a low level in a major midwestern city. 119 
Disk diffusion tests currently remain the simplest screening tests to detect blaKPC-positive 120 
bacteria in clinical microbiology laboratories. 121 
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Table 1. Characteristics of Enterobacteriaceae strains exhibiting in vitro carbapenem non-susceptibility and/or harboring the 223 




Organism Disk diffusion test results –  
Carbapenem antibiotics 




  Ertapenem Imipenem Meropenem Cefepime Ciprofloxacin  Gentamicin  
1 K. pneumoniae R R R R R S + 
- K. pneumoniae R S R    - 
2 E. cloacae * R R R R S S + 
- E. cloacae R S S    - 
3 P. mirabilis I R S S S S + 
- E. coli R S S    - 
- C. freundii I S S    - 
 226 
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Note: S = susceptible, I = intermediate, R = resistant. In additional susceptibility testing, the K. pneumoniae recovered from Patient 1 227 
was intermediately susceptible to tigecycline and susceptible to colistin. Also, the E. cloacae from Patient 2 was intermediately 228 
susceptible to tigecycline and susceptible to colistin.  229 
* recovered from polymicrobial Enterobacteriaceae bacteremia. 230 
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Table 2. Characteristics of patients with bacteremias caused by blaKPC-positive Enterobacteriaceae  
 
 
Note: ICU, intensive care unit; PVD, peripheral vascular disease; DM, diabetes mellitus. A bacteremia was considered hospital-





Admitted from Location at time 
of blood culture 
Source of 
infection 
Type of bacteremia Organism Adequate empirical 
antibiotic treatment 
Outcome 








2 79 Enterocutaneous 
fistula post-
hernia repair 
Long-term care facility 
(St. Louis, Missouri) 











Long-term care facility 
(St. Louis, Missouri) 
Non-ICU Skin/soft tissue Community-acquired, 
healthcare-associated 





published criteria (8). Inadequate empirical antibiotic treatment was defined as no antibiotic given to which the bacteria were 
susceptible within 24 hours of obtaining the positive blood culture (10) 
* recovered from polymicrobial Enterobacteriaceae bacteremia. 
 
 16 
 
